Related by context. All words. (Click for frequent words.) 71 Hypoactive Sexual Desire Disorder 70 Zoraxel 70 Peyronie Disease 68 FSAD 67 Androxal TM 67 JAK Inhibitor 66 Disorder FSAD 66 nalbuphine ER 66 maintain penile erection 66 Testosterone MDTS R 66 AGHD 66 relapsed MM 65 RSD# oral 65 HCV SPRINT 65 Danazol 65 budesonide foam 64 riociguat 64 Zestra R 64 Phase 2b Clinical Trial 64 antiandrogens 64 MAGE A3 ASCI 64 disorder FSAD 64 coadministration 64 Hepatotoxicity 64 eosinophilic asthma 64 elotuzumab 64 Androxal ® 64 VivaGel TM 64 erection hardness 64 Phase III Pivotal 64 Ozarelix 64 GOUT 64 CYT# potent vascular disrupting 64 Valdoxan 64 Ophena TM 63 quadrivalent HPV vaccine 63 CIMZIA ™ 63 invasive candidiasis 63 oral prodrug 63 CCX# 63 dextofisopam 63 Zemplar Capsules 63 plasma pharmacokinetics 63 Female Sexual Dysfunction 63 Tasimelteon 63 female sexual arousal 63 HCV replicon 63 pharmacokinetic interactions 63 LibiGel ® 63 Degarelix 63 Investigational Treatment 63 ELACYT 63 Estradiol 63 Retreatment 63 recurrent glioma 63 dyspareunia 63 Pimavanserin 63 goserelin 63 bremelanotide 63 Meets Primary Endpoint 63 GH deficiency 63 VA# [002] 63 candidemia 63 mGluR5 NAM 63 avanafil PDE5 inhibitor 62 pharmacokinetic characteristics 62 transdermal testosterone 62 pomalidomide 62 velafermin 62 Phase III Clinical Trials 62 HCV RESPOND 2 62 Phase III Clinical Trial 62 Disease Progression 62 Bezielle 62 Female Sexual Arousal 62 Thiovir 62 viral kinetics 62 inhibitor RG# 62 GSK# [002] 62 Interferon Beta 62 MGd 62 Benign Prostatic Hyperplasia 62 Hypogonadism 62 hypogonadal men 62 APTIVUS 62 posaconazole 62 Achieves Primary Endpoint 62 Afatinib 62 agomelatine 62 Aflibercept 62 Silodosin 62 PROSTVAC VF 62 GnRH antagonist 62 PEGINTRON TM 62 diarrhea predominant irritable 62 desire disorder HSDD 62 pharmacokinetic PK profile 62 dysfunctional voiding 62 Elocalcitol 62 hMG 62 Non inferiority 62 X Excite 62 chlamydial infection 62 Multiple Ascending Dose 62 urocortin 2 62 mTOR inhibition 62 GnRH agonists 62 solithromycin 62 Phase 2b Study 62 oral PrEP 62 midstage clinical 62 STRIDE PD 62 Telbivudine 62 cannabinor 62 Overactive Bladder OAB 62 Elagolix 62 dysmenorrhea 62 ziconotide 62 EXJADE 61 Capesaris 61 TACI Ig 61 SILENOR TM 61 sitaxsentan 61 Factor VIIa 61 HeFH 61 pegylated liposomal doxorubicin 61 Phase Ib clinical 61 Rheumatoid Arthritis RA 61 Potent Antiviral Activity 61 galiximab 61 Dasatinib 61 MAS XR 61 R#/MEM # 61 Acute Ischemic Stroke 61 cobiprostone 61 Pharmacokinetics PK 61 micafungin 61 AEG# 61 CANCIDAS 61 pharmacodynamic parameters 61 TYGACIL 61 dose cohort 61 oxcarbazepine 61 prucalopride 61 pharmacokinetic interaction 61 EVIZON 61 Zavesca R 61 Dextofisopam 61 alvespimycin 61 LHRH agonists 61 clevidipine 61 desvenlafaxine succinate 61 clinical pharmacology studies 61 Pegylated Interferon 61 benign prostatic hypertrophy BPH 61 inecalcitol 61 ritonavir boosted 61 Prolongs Survival 61 CERVARIX 61 preclinical pharmacokinetic 61 Phase 2b Trial 61 dose escalation phase 61 Metastatic Prostate Cancer 61 HIV seronegative 61 antiangiogenic therapy 61 ALB # 61 davunetide intranasal AL 61 SILENOR 61 Combination Treatment 61 NATRECOR ® 61 evaluating mipomersen 61 bazedoxifene conjugated estrogens 61 DDP# 61 alfuzosin 61 eltrombopag 61 Avanafil 61 Nonclinical 61 LB# [003] 61 Fibrillex TM 61 PRT# 61 certolizumab 61 dosing cohort 61 trastuzumab Herceptin ® 61 polycythemia vera essential thrombocythemia 61 noninfectious uveitis 61 refractory gout 61 GnRH agonist 61 Squalamine 61 Golimumab 61 HDL Selective Delipidation 61 ACTEMRA TM 61 Newly Diagnosed Multiple Myeloma 61 recurrent glioblastoma multiforme 61 KRN# 61 Heavy menstrual bleeding 61 INCB# [003] 61 Antitumor Activity 61 thymalfasin 61 SPRIX ® 61 serotonin norepinephrine reuptake inhibitor 61 BENICAR HCT 61 Randomized Phase 61 acyclovir Lauriad R 61 prepubertal 61 evaluating tivozanib 61 biologic DMARD 61 biliary tract cancer 60 #mg dose [002] 60 divalproex sodium 60 onset puberty 60 LEUKINE 60 teduglutide 60 Lubiprostone 60 virological response 60 highly immunogenic 60 haematologic 60 elagolix 60 demonstrated antitumor activity 60 protease inhibitor PI 60 Phase IIA 60 lisdexamfetamine dimesylate 60 PDE# inhibitors 60 unprotected receptive anal 60 dose proportionality 60 Protease Inhibitors 60 See CLINICAL PHARMACOLOGY 60 intravesical therapy 60 Phase 2a Clinical Trial 60 LYSTEDA 60 Major Depressive Disorder 60 VP# [004] 60 dose paroxetine mesylate 60 acute mania 60 glucocorticoid induced osteoporosis 60 ENMD # 60 HIV HCV coinfected 60 Tesmilifene 60 BRIM3 60 hematologic toxicity 60 MYCAMINE 60 T1DM 60 INCB# [001] 60 Pivotal Phase 60 Ophena 60 hematological parameters 60 antiretroviral naive 60 sargramostim 60 SSRI SNRI 60 selective modulator 60 polymerase inhibitor 60 NMDA antagonists 60 abacavir Ziagen 60 Diabetic Macular Edema 60 Study Evaluating 60 Aurora Kinase 60 APTIVUS r 60 Solorel TM 60 TBC# 60 YONDELIS 60 Ocrelizumab 60 PRADAXA 60 GLP toxicology studies 60 secondary amenorrhea 60 Mg Uk 60 DXL# 60 huC# DM4 60 neurodevelopmental outcome 60 dopamine partial agonist 60 Demonstrates Positive 60 HuLuc# 60 EDEMA3 trial 60 BEXXAR Therapeutic Regimen 60 decitabine 60 metastatic RCC 60 bacterial vaginosis BV 60 Glypromate 60 TransVax ™ 60 cMET 60 Faropenem 60 IELT 60 Ecallantide 60 ARCALYST ® 60 fosbretabulin 60 diabetic neuropathic pain 60 ostarine 60 PEG SN# 60 K ras mutations 60 Azedra 60 somatostatin analog 60 CTAP# Capsules 60 R# #mg BID 60 C1 Inhibitor 60 Tumor Response 60 phase IIb trial 60 receptor tyrosine kinase inhibitor 60 Randomized Double blind 60 ONTAK 60 teriflunomide 60 CR# vcMMAE 60 masitinib 60 Thorough QT 60 thyrotropin 60 Zenvia ™ 60 Tolerability 60 rFSH 60 mecamylamine 60 AGILECT R 60 preclinically 60 castrate resistant prostate cancer 60 ARIXTRA R 60 CA4P 60 Chlamydia trachomatis infection 60 Pagoclone 60 AA Amyloidosis 60 orally administered inhibitor 60 overactive bladder syndrome 60 canakinumab 60 PSMA ADC 60 Corlux 60 TLK# 60 therapeutic regimens 60 Phase Ib II 60 Dupuytren Disease 60 prospective multicentre 60 #I TM# 60 dyslipidaemia 60 ritonavir boosted lopinavir 60 Decitabine 60 GHRH 60 JVRS 60 Oral Fingolimod 60 pharmacodynamic profiles 60 Juvenile Idiopathic Arthritis 60 Phase IIB 60 Aloxi injection 60 Abciximab 60 IL# PE#QQR 60 lysosomal enzyme iduronate 59 Phase 1a 59 deferiprone 59 pramlintide metreleptin combination 59 Blinatumomab 59 Teriparatide 59 onset idiopathic hypogonadism 59 vasomotor symptoms 59 antiarrhythmic drug 59 Postmenopausal 59 Peginterferon 59 eprotirome 59 ACAPODENE 59 erythropoietic 59 Phenoptin 59 Immunogenicity 59 Mipomersen 59 Clinical Trial Results 59 MEVACOR 59 Antiviral Activity 59 Overactive Bladder 59 venous thromboembolic events 59 menopause contraception 59 VivaGel ™ 59 PRTX 59 Insulin PH# 59 hepatitis C genotype 59 pharmacodynamic profile 59 serum lipid levels 59 Enzastaurin 59 Naive Patients 59 onset diabetes mellitus 59 superficial bladder cancer 59 IM progesterone 59 flavopiridol 59 non nucleoside HCV 59 HCV protease inhibitors 59 Antiangiogenic 59 vardenafil Levitra 59 acitretin 59 prospectively stratified 59 AMEVIVE 59 Prelox 59 TELINTRA 59 Phase Ib study 59 XOMA 3AB 59 MYDICAR ® 59 retrograde ejaculation 59 trastuzumab emtansine T DM1 59 telaprevir dosing 59 EGFR HER2 59 gonadotropins 59 R roscovitine 59 Cardiotoxicity 59 guanfacine extended release 59 hyperphenylalaninemia HPA due 59 Myocet 59 DermaVir Patch 59 overactive bladder symptoms 59 Progestin 59 venlafaxine XR 59 EVIZON TM 59 HspE7 59 Proellex TM 59 myeloproliferative diseases 59 Generalized Anxiety Disorder 59 GW# [003] 59 Velcade bortezomib 59 oral methylnaltrexone 59 Cetrorelix 59 Cipralex ® 59 Androgen 59 torsemide ER 59 clomiphene citrate 59 noscapine 59 DAPT 59 Pharmacologic 59 ALT flares 59 dosage regimens 59 Randomized Double Blind 59 Pharmacokinetic Study 59 AEGR 59 S/GSK# 59 telaprevir VX 59 GSK# [001] 59 Phase IIb Trial 59 virologic responses 59 TKM ApoB 59 Sym# 59 MEND CABG 59 CIMZIA TM certolizumab pegol 59 Atomoxetine 59 phase IIb study 59 isoproterenol 59 double blinded placebo 59 androgen hormone 59 Dalbavancin 59 rhMBL 59 novel VDA molecule 59 undetectable HBV DNA 59 Lysteda 59 dexamethasone Decadron 59 NPH insulin 59 baminercept 59 Hyphanox 59 Helicobacter pylori eradication 59 Renal Cell Carcinoma RCC 59 tumorigenicity 59 PEG PAL 59 multicenter randomized placebo controlled 59 ROTARIX 59 Infusion Reactions Severe 59 HER2 positive metastatic breast 59 #beta HSD1 59 phase Ib 59 primary hypercholesterolemia 59 5alpha reductase 59 Cerebril TM 59 visilizumab 59 Solazed TM 59 Reverset 59 CHAMPION PCI 59 Anturol TM 59 rFVIIa 59 migraine prophylaxis 59 OvaRex ® MAb 59 multicenter Phase II 59 prolactin levels 59 tramiprosate Alzhemed TM 59 dexpramipexole 59 Virulizin ® 59 erectile dysfunction impotence 59 refractory anaplastic astrocytoma 59 ularitide 59 eculizumab therapy 59 Omacetaxine 59 Hiberix 59 Ramoplanin 59 grade cervical intraepithelial 59 DEB# 59 Severe Primary IGFD 59 LibiGel testosterone gel 59 linear pharmacokinetics 59 REYATAZ ritonavir 59 pituitary hormone 59 treat benign prostatic 59 ToGA 59 lomitapide 59 Eltrombopag 59 IPL# 59 IMPACT DCM 59 RGB # 59 latrepirdine 59 Valopicitabine 59 prednisone prednisolone 59 CIMZIA TM 59 RhuDex 59 LAB CGRP 59 OMP #M# 59 subgroup analyzes 59 forodesine 59 including eniluracil ADH 59 pharmacodynamic effects 59 functional dyspepsia 59 Traficet EN 59 Gastrointestinal Stromal Tumors 59 conjugated equine estrogen 59 Tezampanel 59 chemoradiation therapy 59 Pivotal Phase III 59 LT NS# 59 evaluable subjects 59 5 HT2C receptor 59 rindopepimut 59 pegylated interferon alfa 2a 59 pharmacodynamic properties 59 HIV uninfected 59 Mesafem 59 caspofungin 59 Microplasmin 59 Androgen Deprivation Therapy 59 PROMACTA 59 HER2 overexpression 59 efalizumab 59 OMNARIS Nasal Spray 59 abnormal pap smears 59 statin monotherapy 59 lymphocyte counts 58 Elitek 58 antioxidant supplementation 58 Bremelanotide 58 antidepressant efficacy 58 NDA Submission 58 prokinetic agent 58 Methylnaltrexone 58 Relapsing Multiple Sclerosis 58 immunological responses 58 rhGH 58 proctitis 58 pertuzumab 58 Symadex 58 LHRH antagonists 58 mg RDEA# 58 Zoloft sertraline 58 SCIg 58 Pafuramidine 58 hoFH 58 Glufosfamide 58 Prodarsan ® 58 mg/m2 dose 58 postmenopausal estrogen 58 Randomized Clinical Trial 58 HPV-#/# 58 Lixivaptan 58 vaginally administered lidocaine 58 Comorbidities 58 Double Blind Randomized 58 blinded randomized placebo controlled 58 Bacterial Vaginosis 58 Randomized Controlled Trials 58 triiodothyronine 58 endometrial hyperplasia 58 IFN gamma 58 treatment naïve genotype 58 PD LID 58 Pemetrexed 58 morphometric vertebral fractures 58 hyperplasia BPH 58 flutamide 58 p# biomarker 58 PEGPH# 58 Paxil paroxetine 58 Relapsing Remitting Multiple Sclerosis 58 Denufosol 58 mertansine 58 sexual arousal disorder 58 SinuNase TM 58 cinacalcet 58 relapsed ALL 58 URG# targets 58 Bicifadine 58 ovulation suppression 58 Pooled Analysis 58 pegylated IFN 58 PREZISTA ritonavir 58 EFFEXOR XR 58 metastatic malignant 58 hormone estradiol 58 Plus Ribavirin 58 tigecycline 58 Phase 1b clinical trials 58 pain palliation 58 INVEGA ® 58 INC# 58 ORENCIA ® 58 SYMMETRY trial 58 im peramivir 58 antimuscarinic 58 aminotransferases 58 pan HDAC inhibitor 58 TDF FTC 58 recurrent venous thromboembolism 58 phase IIb clinical 58 anti androgen 58 Hematologic 58 Panzem R NCD 58 Clostridium difficile Infection 58 EFAPROXYN 58 ataluren 58 angiotensin analog 58 VFEND 58 Dapagliflozin 58 Phase 1b trial 58 Antiviral Therapy 58 serum testosterone 58 Clinical Outcome 58 Serious adverse reactions 58 Effexor venlafaxine 58 vesicoureteral reflux 58 osteosarcomas 58 nucleoside analog 58 Randomized controlled 58 Atopic Dermatitis 58 follicular lymphomas 58 sipuleucel T 58 treatment naive genotype 58 TEAEs 58 AVODART 58 Nilotinib 58 endometriosis ovarian cysts 58 prasterone 58 preclinical efficacy 58 ARIKACE ™ 58 SPRYCEL ® 58 Soft Tissue Sarcoma 58 corrected QT interval 58 antiretroviral naïve 58 tanespimycin 58 VAPRISOL 58 oral rivaroxaban 58 lenalidomide dexamethasone 58 EndoTAG TM -1 58 Proxinium TM 58 gallium nitrate 58 HuMax EGFr 58 MERLIN TIMI 58 CaPre TM 58 taxane resistant 58 Safinamide 58 ARB telmisartan 58 postexposure prophylaxis 58 ganetespib 58 Immunotherapeutic 58 Triolex 58 trospium 58 Phase IIa trial 58 benign prostatic hypertrophy 58 treat premature ejaculation 58 Fludarabine 58 dose limiting toxicities 58 PREZISTA r 58 Toxicities 58 SAR# [002] 58 Teriflunomide 58 JAK inhibitor 58 Completes Patient Enrollment 58 RISPERDAL ® 58 JAK inhibitors 58 Azacitidine 58 buprenorphine naloxone 58 FASLODEX 58 Drug Candidate 58 LNG IUS 58 Phase IIIb clinical 58 Navelbine ® 58 squalamine 58 delafloxacin 58 Vitaxin 58 Pharmacodynamic 58 paroxetine sertraline 58 Sudhir Agrawal D.Phil 58 BCX# 58 Phase 2a trial 58 indibulin 58 multicenter placebo controlled 58 PSN# [002] 58 2A receptor agonist 58 Spiegelmer ® 58 paclitaxel Taxol R 58 prostate cancer CRPC 58 Multimeric 58 receptor inhibitor 58 HDAC Inhibitor 58 pharmacological therapies 58 mapatumumab 58 NP2 Enkephalin 58 E1 INT TM 58 meta regression 58 stated Michelle Berrey 58 rectal microbicides 58 Allogeneic 58 serum cortisol 58 dose proportional pharmacokinetics 58 Survival Benefit 58 ADAGIO study 58 Darunavir 58 Testosterone MDTS ® 58 PANSS scores 58 Hormone Replacement 58 trastuzumab Herceptin R 58 placebo controlled clinical 58 ALN TTR# 58 ACCORD Lipid 58 antitumor effect 58 thrombin inhibiting aptamer 58 FOSRENOL ® 58 Nocturia 58 FOLOTYN ® 58 KNS # 58 Vaginal Gel 58 orally dosed 58 IMA# 58 citalopram Celexa 58 dopaminergic therapy 58 placebo controlled clinical trials 58 tezampanel 58 IFN α 58 interferon IFN 58 Sipuleucel T 58 Initiates Clinical 58 TNF antagonist 58 trastuzumab DM1 T DM1 58 busulfan 58 pharmacokinetic studies 58 Anti Tumor Activity 58 Rakai Uganda 58 Personalized Immunotherapy 58 Serious Adverse Events 58 Desmopressin 58 myelofibrosis polycythemia vera 58 CCR5 mAb 58 trodusquemine 58 CYT# QbG# 58 Diabetic Neuropathy 58 antiangiogenic agents 58 Tanespimycin 58 HIV lipodystrophy 58 bosentan 58 muscarinic 58 Vernakalant 58 Noxafil 58 keloid scarring 58 LHRH agonist 58 Premature Ejaculation 58 rhIGF-I/rhIGFBP-3 58 Placebo Controlled Trial 58 Ostarine 58 REVLIMID ® 58 suppressive therapy 58 Prostate AdenoCarcinoma Treatment 58 invasive aspergillosis 58 MYDICAR 58 Benign Prostatic Hyperplasia BPH 58 MEK Inhibitor 58 Forodesine HCl 58 probiotic supplementation 58 Menerba 58 Cimzia ® certolizumab pegol 58 aplindore 58 #D#C# 58 Cariprazine 58 gonadotropin 58 Trial Evaluating 58 LY# [003] 58 Tolvaptan 58 adecatumumab 58 efavirenz EFV 58 tegaserod 58 radezolid 58 Prospective Randomized 58 pharmacokinetic PK study 58 Clinical Trial Data 58 Sapacitabine 58 Viramidine 58 Akathisia 58 Hepatocellular Carcinoma HCC 58 antiepileptics 58 reuptake inhibitor 58 RECOTHROM R 58 colorectal liver metastases 58 enzastaurin 58 VIRAMUNE XR 58 Doxil ® 58 Androxal 58 Follicle Stimulating Hormone 57 Bipolar Mania 57 Nexavar sorafenib 57 Parathyroid Hormone 57 vascular endothelial dysfunction 57 Meta analyzes 57 TMC# [002] 57 topically administered 57 RhuDex ® 57 Fabry Disease 57 oxycodone CR 57 idraparinux 57 Triapine R 57 Systemic Sclerosis 57 REMINYL ® 57 HBeAg negative 57 EOquin TM 57 Adjunctive Therapy 57 oral ridaforolimus 57 pharmacodynamic PD 57 serum estradiol 57 GALNS 57 AVOREN 57 aripiprazole Abilify 57 tolterodine 57 constipation OIC 57 antibody titer 57 maximally tolerated dose 57 sorafenib Nexavar 57 eliglustat tartrate 57 paricalcitol 57 Plicera 57 motesanib diphosphate 57 AGILECT ® 57 Chronic Prostatitis 57 comparator arm 57 pradefovir 57 BAL# [002] 57 conjugated estrogens 57 GERD migraine headaches 57 thromboembolic disease 57 genotypic resistance 57 oral deforolimus 57 Ranolazine 57 Onrigin TM 57 HGS ETR2 57 myopathy rhabdomyolysis 57 HGS ETR1 57 Bipolar Depression 57 nab paclitaxel 57 ISTODAX 57 LymphoStat B belimumab 57 chronic eosinophilic leukemia 57 CLINICAL PHARMACOLOGY 57 hypoactive sexual desire 57 PREGNANT Study 57 Initiate Phase 57 bicifadine 57 alfa 2a 57 LOVENOX R 57 clomipramine 57 Phase III ADT 57 uricase 57 Phase III Trial 57 neuropsychiatric diseases 57 #F FDG PET 57 tolevamer 57 randomized Phase 2b 57 oral diclofenac 57 Fulvestrant 57 zidovudine AZT 57 receptive anal sex 57 EXPAREL TM 57 Testosterone deficiency 57 ORMD 57 intravenous bisphosphonates 57 MoxDuo TM IR 57 ritonavir boosted atazanavir 57 Bosentan 57 solifenacin 57 acamprosate 57 Alzhemed TM 57 interferon alfa 2b 57 analgesic efficacy 57 BeneFIX 57 LUTS 57 Linagliptin 57 follitropin alfa 57 oral talactoferrin 57 BOLDER II 57 Bioequivalence 57 adrenocorticotropic hormone ACTH 57 efficacy endpoint 57 serologic testing 57 mGluR2 57 pharmacokinetic PK 57 ENGAGE AF TIMI 57 TMC# r 57 IgG1 antibodies 57 Oral NKTR 57 placebo controlled studies 57 ritonavir boosting 57 herpetic keratitis 57 chronic prostatitis 57 PSD# 57 Controlled Trial 57 Iloperidone 57 IBS C 57 QLT# 57 docetaxel chemotherapy 57 Pre Exposure Prophylaxis 57 Angioedema 57 initiate Phase 1b 57 Civacir 57 pharmacologically active isomer 57 avanafil 57 ANCHOR trial 57 Detrol Detrol LA 57 OvaRex R 57 virologic response 57 Kahalalide F 57 tasimelteon 57 Irinotecan 57 miglustat 57 leukotriene receptor antagonists 57 HCV infected 57 carcinoid syndrome 57 transaminase elevations 57 Archexin 57 tenofovir emtricitabine 57 ceftazidime 57 LUX Lung 57 Phase 2b study 57 XP# XP# 57 naltrexone hydrochloride 57 CRLX# 57 Pharmacokinetic PK 57 hypogonadotropic hypogonadism 57 NUCYNTA R 57 MKC# MT 57 Tracleer R 57 enoximone 57 prospectively randomized 57 estradiol gel indicated 57 pyridostigmine 57 preclinical toxicology 57 FOSRENOL R 57 Erectile Dysfunction ED 57 Thalomid ® 57 ancrod 57 PYY #-# 57 Sanctura XR 57 Pivotal Trial 57 Insulin detemir 57 omega interferon 57 Adjuvant Treatment 57 PC DAC Exendin 57 INTEGRILIN 57 lipid parameters 57 Improves Outcomes 57 serum calcium 57 iniparib 57 ZYBRESTAT fosbretabulin 57 clinical trials Multikine 57 MVA MUC1 IL2 57 d4T stavudine Zerit 57 prostate cancer CaP 57 PGL# 57 genital arousal 57 parkinsonian symptoms 57 BoNTA 57 Increlex R 57 Pivotal Study 57 MDS AML 57 CEQ# 57 Prolactin 57 efficacy tolerability 57 luteal 57 alkylating agent 57 perinatal outcomes 57 vasodilatation 57 poliovirus vaccine 57 aminotransferase 57 First Patient Dosed 57 Lupus Drug 57 alagebrium 57 RezularTM 57 Renal Insufficiency 57 Cleviprex TM clevidipine 57 trivalent influenza vaccine 57 protease inhibitors PIs 57 postoperative ileus 57 Carfilzomib 57 Ziprasidone 57 symptomatic BPH 57 alicaforsen enema 57 opioid dependent 57 reactogenicity 57 Metabolic Efficiency 57 Preclinical Study 57 paroxetine Paxil 57 phase IIIb 57 HCD# [002] 57 OAB symptoms 57 Initiated Phase 57 vWD 57 DMARDS 57 CoFactor